Bellerophon Therapeutics, Inc.
NASDAQ: BLPH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Craig R. Jalbert CIRA
- Employees
- 18
- Headquarters
- Warren, United States
- IPO year
- 2015
- Market cap
- $146.8K
- Website
- https://bellerophon.com
Loading BLPH…
Loading profile data…Frequently asked questions about BLPH
What does Bellerophon Therapeutics, Inc. (BLPH) do?
Bellerophon Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company primarily focused on developing novel therapies for various cardiopulmonary conditions. Its flagship product is INOpulse, a proprietary platform designed to deliver pulsatile nitric oxide, specifically targeting pulmonary hypertension (PH). The company is active...
Where does BLPH trade?
Bellerophon Therapeutics, Inc. (BLPH) trades on the NASDAQ Capital Market.
What sector is BLPH in?
Bellerophon Therapeutics, Inc. (BLPH) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Bellerophon Therapeutics, Inc.?
Craig R. Jalbert CIRA is the chief executive officer of Bellerophon Therapeutics, Inc. (BLPH).
Where is Bellerophon Therapeutics, Inc. headquartered?
Bellerophon Therapeutics, Inc. is headquartered in United States.
Does BLPH pay a dividend?
Yes — Bellerophon Therapeutics, Inc. (BLPH) paid a trailing twelve-month dividend of USD 0.02 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did BLPH go public?
Bellerophon Therapeutics, Inc. (BLPH) completed its initial public offering in 2015.